Systematic Review of Genomic‐Based Risk Stratification in Localised Prostate Cancer Treatment Optimisation: Clinical Impact and Health Economic Evidence
Cancer Medicine · 2026-03 · 15 (3)
DOI: 10.1002/cam4.71690 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cancer Medicine, online erschienen am 09.03.2026. Verfasst von Juntao Lyu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Health Services Research Unit, Centre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Melbou…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Genomics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Advanced Genomics Collaboration.
Abstract (Originalsprache)
Background
Several genomic risk stratification tests are available to predict the risk of metastasis and mortality for prostate cancer patients at the time of diagnosis. However, the evidence supporting the clinical utility of genomic risk stratification tools is fragmented, posing challenges in assessing their real‐world clinical impact and cost‐effectiveness.
Objective
To review and summarise the clinical impact and health economic evidence of the four types of genomic risk stratification tests and to validate their clinical impact and health economic evaluation outcomes.
Method
A systematic search was conducted in the Scopus, EMB Reviews and Google Scholar databases. Eligible publications were selected based on the eligible patient cohort, genomic test, initial NCCN risk categories, the clinical impact of the genomic test and health evaluation outcomes.
Conclusion
26 clinical impact evidence studies and four health economic evaluation studies were included. Most clinical studies indicated that genomic tests reclassified patients' risk predictions into both lower‐ and higher‐risk groups. The reclassification outcomes influenced patients' treatment decisions between active surveillance and radical treatment. The prognostic value of the genomic tests was validated in terms of biopsy upgrade, metastasis and death. The limited number of health economic studies reported that the Oncotype DX Prostate Score and ProMark were cost‐effective, while the Prolaris was cost‐saving in the US but not in Canada. The evaluation of the Decipher Genomic Classifier at the time of diagnosis was not available. More long‐term clinical evidence is needed, as are updated health economic evaluations, to determine the cost‐effectiveness of integrating genomic risk stratification into prostate cancer treatment decision‐making in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Cancer Health Services Research Unit, Centre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
- Collaborative Centre for Genomic Cancer Medicine, The University of Melbourne, Melbourne, VIC, Australia.
- Department of Surgery, The University of Melbourne, Melbourne, VIC, Australia.
- Department of Urology, Royal Melbourne Hospital, Parkville, VIC, Australia.
- Centre for Health Services Research in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
ORCID-Profile: Juntao Lyu
Förderung
- The Advanced Genomics Collaboration
Zitieren
APA
Lyu, J., He, F., Corcoran, N. M., Chen, G., & Akbarzadeh Khorshidi, H. (2026). Systematic Review of Genomic‐Based Risk Stratification in Localised Prostate Cancer Treatment Optimisation: Clinical Impact and Health Economic Evidence. Cancer Medicine, 15(3). https://doi.org/10.1002/cam4.71690
Vancouver
Lyu J, He F, Corcoran NM, Chen G, Akbarzadeh Khorshidi H. Systematic Review of Genomic‐Based Risk Stratification in Localised Prostate Cancer Treatment Optimisation: Clinical Impact and Health Economic Evidence. Cancer Medicine. 2026;15(3). doi:10.1002/cam4.71690
BibTeX
@article{Lyu2026,
author = {Lyu, Juntao and He, Fan and Corcoran, Niall M and Chen, Gang and Akbarzadeh Khorshidi, Hadi},
title = {Systematic Review of Genomic‐Based Risk Stratification in Localised Prostate Cancer Treatment Optimisation: Clinical Impact and Health Economic Evidence},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {3},
doi = {10.1002/cam4.71690}
}
EUVIMED